End-stage renal disease and thrombophilia

Hamostaseologie

Volumn 36, Issue 2, 2016, Pages 103-107

  Bauer, Alexander ^a   Limperger, Verena ^a   Nowak Göttl, Ulrike ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Chronic kidney disease; Organ failure; Thrombophilia; Thrombosis

Indexed keywords

ARTERIOVENOUS FISTULA; CATHETER COMPLICATION; CATHETER MALFUNCTION; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; GRAFT REJECTION; HEMODIALYSIS; HUMAN; KIDNEY TRANSPLANTATION; LIVING DONOR; LUNG EMBOLISM; PERITONEAL DIALYSIS; REVIEW; SHUNT THROMBOSIS; THROMBOPHILIA; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM; CAUSALITY; COMORBIDITY; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; GERMANY; KIDNEY FAILURE, CHRONIC; META ANALYSIS; MORTALITY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

CAUSALITY; COMORBIDITY; EVIDENCE-BASED MEDICINE; GERMANY; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RENAL DIALYSIS; RISK FACTORS; SURVIVAL RATE; THROMBOPHILIA; TREATMENT OUTCOME;

EID: 84971011029     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-14-11-0063     Document Type: Review

References (51)

1. Kim WY, Huh JW, Lim CM ET AL: Analysis of progression in risk, injury, fail, loss and end-stage renal disease classification on outcome in patients with severe sepsis and septic shock. J Crit Care 2012; 27: 104.e1-7:
2. Rayane T, Haddoum E: Chronic renal failure in Algeria. Renal replacement therapy strategies and progression. Saudi Kidney Dis Transplant Bull 1993; 4 (suppl 1) 118.
3. Kamoun A, Jawahdou F, Hachicha J et al. Causes of end-stage chronic kidney failure in children in Tunisia. Arch Pediatr 1997; 4: 196-198.
4. Barsoum RS: End-stage renal disease in the developing world. Artif Organs 2002; 26: 735-736.
5. Schwab SJ, Harrington JT, Singh A et al. Vascular access for hemodialysis. Kidney Int 1999; 55: 2078-2090.
6. Danis R, Ozmen S, Akin D et al. Thrombophilias and arteriovenous fistula dysfunction in maintenance hemodialysis. J Thromb Thrombolysis 2009; 27: 307-315.
7. Allen RDM, Michie CA, Murie JA, Morris PJ. Deep venous thrombosis after renal transplantation. Surg Gynecol Obstet 1987; 164: 137-142.
8. Humar A, Johnson EM, Gillingham KJ. Venous thromboembolic complications after kidney and kidney pancreas transplantation. Transplantation 1998; 65: 229-234.
9. Torry RJ, Labarrere CA, Gargiulo P, Faulk WP. Natural anticoagulant and fibrinolytic pathways in renal allograft failure. Transplantation 1994; 58: 926-931.
10. Irish A. Renal allograft thrombosis: can thrombophilia explain the inexplicable? Nephrol Dial Transplant 1999; 14: 2297-2303.
11. Boots JM, Christiaans MH, Van Duijnhoven EM et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. Transplantation 2002; 74: 1703-1709.
12. Bell DD, Rosental JJ. Arteriovenous graft life in chronic hemodialysis. A need for prolongation. Arch Surg 1988; 123: 1169-1172.
13. Fischereder M1, Göhring P, Schneeberger H et al. Early loss of renal transplants in patients with thrombophilia. Transplantation 1998; 65: 936-939.
14. Andrassy J, Zeier M, Andrassy K. Do we need screening for thrombophilia prior to kidney transplantation? Nephrol Dial Transplant 2004; 19 (suppl 4): iv64-iv68.
15. Friedman GS, Meier-Kriesche HU, Kaplan B et al. Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis. Transplantation 2001; 72: 1073-1078.
16. Singh A, Stablein D, Tejani A. Risk factors for vascular thrombosis in pediatric renal transplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 1997; 63: 1263-1267.
17. Nampoory MR, Das KC, Johny KV et al. Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation. Am J Kidney Dis 2003; 42: 797-805.#
18. O'Shea SI, Lawson JH, Reddan D et al. Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg 2003; 38: 541-548.
19. Fukasawa M, Matsushita K, Kamiyama M et al. The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis 2003; 41: 637-642.
20. Ataç B, Yakupoglu U, Ozbek N et al. Role of genetic mutations in vascular access thrombosis among hemodialysis patients waiting for renal transplantation. Transplant Proc 2002; 34: 2030-2032.
21. Shemin D1, Lapane KL, Bausserman L et al. Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. J Am Soc Nephrol 1999; 10: 1095-1099.
22. Hernández E, Praga M, Alamo C et al. Lipoprotein( a) and vascular access survival in patients on chronic hemodialysis. Nephron 1996; 72: 145-149.
23. Valeri A, Joseph R, Radhakrishnan. A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis patients. J Clin Nephrol 1999; 51: 116-121.
24. LeSar CJ, Merrick HW, Smith MR. Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. J Am Coll Surg 1999; 189: 73-81.
25. Knoll GA, Wells PS, Young D et al. Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol 2005; 16: 1108-1114.
26. Klamroth R, Orlovic M, Fritsche I et al. The influence of thrombophilic risk factors on vascular access survival in chronic dialysis patients in a retrospective evaluation. VASA 2013; 42: 32-39.
27. Salmela B, Hartman J, Peltonen S et al. Thrombophilia and arteriovenous fistula survival in ESRD. Clin J Am Soc Nephrol 2013; 8: 9628.
28. Palomo I, Pereira J, Alarcón M et al. Vascular access thrombosis is not related to presence of antiphospholipid antibodies in patients on chronic hemodialysis. Nephron 2002; 92: 957-958.
29. Hojs R, Gorenjak M, Ekart R et al. Homocysteine and vascular access thrombosis in hemodialysis patients. Ren Fail 2002; 24: 215-222.
30. Adler S, Szczech L, Qureshi A et al. IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis. Clin Nephrol 2001; 56: 428-434.
31. Födinger M, Mannhalter C, Pabinger I et al. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. Nephrol Dial Tranansplant 1996; 11; 668-672.
32. Meyer M, Laux G, Scherer S et al. No association of factor V Leiden, prothrombin G20210A, and MTHFR C677T gene polymorphisms with kidney allograft survival: a multicenter study. Transplantation 2007; 83: 1055-1058.
33. Ocak G, Lijfering WM, Verduijn M et al. Risk of venous thrombosis in patients with chronic kidney disease: identification of high-risk groups. J Thromb Haemost 2013; 11: 627-633.
34. Takemoto S, Terasaki PI, Cecka JM et al. Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. The UNOS Scientific Renal Transplant Registry. N Engl J Med 1992; 327: 834-839.
35. Lim WH, Clayton P, Wong G et al. Outcomes of kidney transplantation from older living donors. Transplantation 2013; 95: 106-113.
36. Kute VB, Vanikar AV, Shah PR et al. Outcome of living and deceased donor renal transplantation in patients aged >55 years: A single-center experience. Indian J Nephrol 2014; 24: 9-14.
37. Tasaki M, Saito K, Nakagawa Y et al. 20-year analysis of kidney transplantation: a single center in Japan. Transplant Proc 2014; 46: 437-441.
38. Aktas S, Boyvat F, Sevmis S et al. Analysis of vascular complications after renal transplantation. Transplantation Proc 2011; 43: 557-561.
39. Gruber SA, Chavers B, Payne WD et al. Allograft renal vascular thrombosis--lack of increase with cyclosporine immunosuppression. Transplantation 1989; 47: 475-478.
40. Heidenreich S, Dercken C, August C et al. High rate of acute rejections in renal allograft recipients with thrombophilic risk factors. J Am Soc Nephrol 1998; 9: 1309-1313.
41. Hocher B, Slowinski T, Hauser I et al. Association of factor V Leiden mutation with delayed graft function, acute rejection episodes and long-term graft dysfunction in kidney transplant recipients. Thromb Haemost 2002; 87: 194-198.
42. Heidenreich S, Junker J, Wolters H et al. Outcome of kidney transplantation in patients with inherited thrombophilia: data of a prospektive study. J Am Soc Nephrol 2003; 14: 234-249.
43. Jacquet A, Pallet N, Kessler M et al. Outcome of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transplant Int 2011; 24; 582-587.
44. Su Z, Wang X, Gao X et al. Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease. I Intern Med 2014; 276: 470-485.
45. Koester BH, Köveker GB, Pötzsch B et al. Hereditäre Thrombophilie als Ursache rezidivierender Transplantatthrombosen. Chirurg 1993; 64: 809-812.
46. Oh J, Schaefer F, Veldmann A et al. Heterozygous prothrombin gene mutation: a new risk factor for early renal allograft thrombosis. Transplantation 1999; 68: 575-578.
47. Fischereder M, Schneeberger H, Lohse P et al. Increased rate of renal transplant failure in patients with the G20210A mutation of the prothrombin gene. Am J Kidney Dis 2001; 38: 1061-1064.
48. Ghisdal L, Broders N, Wissing KM et al. Thrombophilic factors do not predict outcomes in renal transplant recipients under prophylactic acetylsalicylic acid. Am J Transplant 2010; 10: 99-105.
49. Ghisdal L, Broeders N, Wissing KM et al. Thrombophilic factors in stage V chronic kidney disease patients are largely corrected by renal transplantation. Nephrol Dial Transplant 2011; 26: 2700-2750.
50. De Stefano V, Rossi E. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. Thromb Haemost 2013; 110: 697-705.
51. KDIGO Clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3): S1-155.